Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 18/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylalanine SCHEMBL4101431 | 1.00 | P2RY12 (0.57) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| Phenylalanine SCHEMBL4003655 | 0.96 | P2RY12 (0.53) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3922518 | 0.93 | P2RY12 (0.65) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3928973 | 0.82 | P2RY12 (0.64) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4103128 | 0.79 | P2RY12 (0.79) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3934955 | 0.79 | P2RY12 (0.63) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4737004 | 0.77 | P2RY12 (0.75) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3933171 | 0.76 | P2RY12 (0.64) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4004918 | 0.76 | P2RY12 (0.75) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4736388 | 0.75 | P2RY12 (0.73) | P2RY12CYP2C9CYP3A4CHRM2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186876-A1 | Pyridine Analogues II | ASTRAZENECA AB (SE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186876-A1 | Pyridine Analogues II | P2RY12, P2RY11, P2RY6 | P2RY12 1/4885CYP2C9 155/4885CYP3A4 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.